EXACT Sciences Co. (EXAS) Receives $50.97 Average Target Price from Analysts

Shares of EXACT Sciences Co. (NASDAQ:EXAS) have received an average rating of “Buy” from the eighteen research firms that are presently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $50.97.

A number of brokerages recently commented on EXAS. Robert W. Baird lowered EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price objective for the company. in a research report on Monday, November 13th. Leerink Swann reiterated an “outperform” rating and issued a $67.00 price objective (up from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Bank of America lifted their price objective on EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, November 29th. BTIG Research lowered EXACT Sciences from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 1st. Finally, Zacks Investment Research lowered EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd.

In other news, insider Kevin T. Conroy sold 123,512 shares of EXACT Sciences stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $52.58, for a total transaction of $6,494,260.96. Following the transaction, the insider now owns 953,564 shares in the company, valued at approximately $50,138,395.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP D Scott Coward sold 1,665 shares of EXACT Sciences stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the transaction, the senior vice president now owns 37,558 shares in the company, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 610,433 shares of company stock worth $34,341,306. Company insiders own 4.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of EXACT Sciences by 8.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after purchasing an additional 700,051 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of EXACT Sciences by 1.2% during the 2nd quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock valued at $243,518,000 after purchasing an additional 80,589 shares in the last quarter. Fred Alger Management Inc. bought a new position in shares of EXACT Sciences during the 2nd quarter valued at about $84,177,000. Lord Abbett & CO. LLC lifted its holdings in shares of EXACT Sciences by 59.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after purchasing an additional 875,527 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of EXACT Sciences by 32.7% during the 2nd quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after purchasing an additional 571,796 shares in the last quarter. Institutional investors and hedge funds own 82.39% of the company’s stock.

Shares of EXACT Sciences (NASDAQ:EXAS) traded down $2.44 during trading hours on Tuesday, hitting $52.62. The stock had a trading volume of 6,302,800 shares, compared to its average volume of 1,960,000. EXACT Sciences has a 52 week low of $16.95 and a 52 week high of $63.60. The firm has a market capitalization of $6,300.00, a price-to-earnings ratio of -45.76 and a beta of 0.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. During the same period last year, the company posted ($0.36) earnings per share. The firm’s quarterly revenue was up 158.4% compared to the same quarter last year. analysts predict that EXACT Sciences will post -1.1 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/12/exact-sciences-co-exas-receives-50-97-average-target-price-from-analysts.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply